[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France].
Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en France.
Breast cancer
Cancer du sein
ERBB2
Guidelines
HER2
Hybridation in situ
Immunohistochemistry
Immunohistochimie
In situ hybridization
Recommandations
Journal
Annales de pathologie
ISSN: 0242-6498
Titre abrégé: Ann Pathol
Pays: France
ID NLM: 8106337
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
24
03
2021
revised:
01
07
2021
accepted:
11
07
2021
pubmed:
17
8
2021
medline:
16
11
2021
entrez:
16
8
2021
Statut:
ppublish
Résumé
The last international guidelines on HER2 determination in breast cancer have been updated in 2018 by the American Society of Clinical Oncology and College of American Pathologists, on the basis of a twenty-year practice and results of numerous clinical trials. Moreover, the emerging HER2-low concept for 1+ and 2+ non amplified breast cancers lead to refine French practices for HER2 status assessment. The GEFPICS group, composed of expert pathologists, herein presents the latest French recommendations for HER2 status evaluation in breast cancer, taking into account the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, HER2 status assessment remains one of the most important biomarkers in breast cancer and its quality guaranties the optimal patients' care. French pathologists' commitment in theranostic biomarker quality is more than ever required to provide the most efficient cares in oncology.
Identifiants
pubmed: 34393014
pii: S0242-6498(21)00191-7
doi: 10.1016/j.annpat.2021.07.014
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Practice Guideline
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
507-520Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.